The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1414
ISSUE1414
April 15, 2013
Teduglutide Injection (Gattex) for Short Bowel Syndrome
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Teduglutide Injection (Gattex) for Short Bowel Syndrome
April 15, 2013 (Issue: 1414)
The FDA has approved teduglutide (te due’ gloo tide;
Gattex – NPS), a recombinant DNA analog of
glucagon-like peptide-2 (GLP-2), for treatment of short
bowel syndrome (SBS) in adults who are dependent
on parenteral support.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.